Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $19 from $20 and keeps a Buy rating on the shares. In the wake of Q3 financial results, the firm caught up with CervoMed CFO Bill Elder for further insights, the analyst tells investors in a research note. At the end of Q3 the company has roughly $27.3M in cash, which, per management’s view, is expected to fund operations through 3Q26, the analyst notes.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed reports Q3 EPS (84c), consensus (56c)
- CervoMed’s Promising Phase 3 Trial and Strategic Financial Position Support Buy Rating
- CervoMed upgraded to Buy from Neutral at H.C. Wainwright
- CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating
- CervoMed announces FDA alignment on neflamapimod registration path